MINI LONG - VERTEX PHARMACEUTICALS | Delayed Deutsche Boerse AG 13:32:16 2024-05-23 EDT | ||
| 23.52 EUR | +0.77% |
|
| Current month | +26.11% | ||
| 1 month | +19.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 23.52 | +0.77% |
| 24-05-22 | 23.34 | +4.80% |
| 24-05-21 | 22.27 | -3.59% |
| 24-05-20 | 23.1 | +1.67% |
| 24-05-17 | 22.72 | +1.93% |
Delayed Quote Deutsche Boerse AG
Last update May 23, 2024 at 01:32 pm
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Citi
|
| WKN | KA4XNU |
| ISIN | DE000KA4XNU0 |
| Date issued | 2019-10-04 |
| Strike | 197.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.81 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.75 € |
|---|---|
| Lowest since issue | 1.17 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
450.8
USD
Average target price
462.8
USD
Spread / Average Target
+2.66%
- Stock Market
- Certificates
- Certificat
